

U.S. Serial No.: To be assigned
(371 Nat'l Entry of PCT/US03/10976)
Preliminary Amendment Filed 10/12/2004




IN THE CLAIMS

Please amend the claims as follows:

1. (ORIGINAL) A composition comprising a TNP-470 conjugated to a polymer, wherein the polymer is water soluble and has a molecular weight in the range of 100Da to 800 kDa.
2. (ORIGINAL) The composition of claim 1, wherein the polymer has a molecular weight no greater than 60 kDa.
3. (ORIGINAL) The composition of claim 1, wherein the polymer has a molecular weight in the range of 15 to 40 kDa.
4. (ORIGINAL) The composition of claim 1, wherein the polymer is a hydroxypropyl(meth)acrylamide-methacrylic acid copolymer.
5. (ORIGINAL) The composition of claim 1, further comprising a peptide linker between the TNP-470 and the polymer.
6. (ORIGINAL) The composition of claim 1, further comprising a targeting ligand.

U.S. Serial No.: To be assigned
(371 Nat'l Entry of PCT/US03/10976)
Preliminary Amendment Filed 10/12/2004

7. (ORIGINAL) The composition of claim 4, comprising the structure:




wherein y is in the range of 0.04-20 and x is in the range of 80-99.96.

U.S. Serial No.: To be assigned
(371 Nat'l Entry of PCT/US03/10976)
Preliminary Amendment Filed 10/12/2004

8. (CURRENTLY AMENDED) A method of treating an angiogenic disease comprising administering a composition of ~~claims~~ claim 1 → to a mammal in need thereof.
9. (ORIGINAL) The method of claim 8, wherein angiogenic disease is a solid tumor.
10. (ORIGINAL) A method for decreasing neurotoxicity of TNP-470, comprising conjugating the TNP-470 to a polymer, wherein the polymer is water soluble and has a molecular weight in the range of 100 Da to 800 kDa.
11. (CURRENTLY AMENDMED) The ~~composition~~ method of claim + 10, wherein the polymer has a molecular weight no greater than 60 kDa.
12. (CURRENTLY AMENDMED) The ~~composition~~ method of claim + 10, wherein the polymer has a molecular weight in the range of 15 to 40 kDa.
13. (ORIGINAL) The method of claim 10, wherein the polymer is a hydroxypropyl(meth)acrylamide-methacrylic acid copolymer.
14. (ORIGINAL) The method of claim 10, further comprising a peptide linker between the antiangiogenic agent and the polymer.

U.S. Serial No.: To be assigned
(371 Nat'l Entry of PCT/US03/10976)
Preliminary Amendment Filed 10/12/2004

15. (ORIGINAL) The method of claim 10, comprising the structure:




wherein y is in the range of 0.04-20 and x is in the range of 80-99.96.

U.S. Serial No.: To be assigned
(371 Nat'l Entry of PCT/US03/10976)
Preliminary Amendment Filed 10/12/2004

16. (ORIGINAL) The method of claim 15, wherein y is 5-10 and x is 90-95.

17. (ORIGINAL) An HPMA-TNP-470 conjugate comprising the structure:



Wherein x is 90-95 and y is 5-10.